In this webinar, OSE Immunotherapeutics joins key opinion leaders Dr Stephen Liu, associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center (Washington DC, United States) and Professor Benjamin Besse, medical oncologist and director of clinical research at the Gustave Roussy Institute (Villejuif, France), to discuss the current unmet in need in lung cancer therapeutics and the development landscape of OSE’s cancer vaccine, Tedopi.
About OSE Immunotherapeutics
OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immuno-oncology and immuno-inflammation. At the forefront of its portfolio is Tedopi, a revolutionary cancer vaccine that has recently demonstrated promising outcomes in a Phase III study involving non-small cell lung cancer patients facing secondary resistance following checkpoint inhibitor treatment. The company’s R&D pipeline is robust and diverse, ensuring that its progress remains resilient and independent of any singular subsector.
